Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

"Honestly, I'm quite alarmed by what we see in the U.S. now," Novo Nordisk President and CEO Lars Fruergaard Jorgensen told ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

Those results were sufficient for the trial to meet its primary endpoints, Novo Nordisk said in a Friday release. Digging deeper into the data, 37% of patients treated with semaglutide achieved ...

In the trial, semaglutide 2.4 mg appeared to have a ... executive vice president and head of Development at Novo Nordisk. “Among people with overweight or obesity, one in three live with MASH.

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that the ...